VC firms
Edit
Delaware Crossing Investor Group
https://www.delawarecrossing.org/Last activity: 05.10.2021
Active
WE ARE DELAWARE CROSSING INVESTOR GROUP
Persons 3
| Date | First Name | Last Name | Title | Location | |||
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Mark | Mitchell | Managing Director & Screening Committee Chair | Sign up to see | ||||
| Benjamin David | Novak | Angel Investor | Sign up to see |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 8, 2020 | Why I’m optimistic about Philly tech, and why you should be, too: Notes from a former investor | It’s really freakin’ hard to build a company. In fact, there’s no rational reason to do so. According to private equity research company CB Insights, 42% of the time your startup will fail due to lack of a market need for the product, about... |
| Feb 21, 2018 | New Castle’s ThruPore raises $540,000 from local investors | ThruPore Technologies, a catalysis technology company headquartered in New Castle, has raised $540,000 in a seed round led by Philadelphia-based angel investor group Robin Hood Ventures alongside Delaware Crossing Investor Group (DCIG). The... |
| Aug 27, 2012 | Attention life science startups: Super angel consortium seeks to fill investment void | “Venture capital firms have invested in life science companies, but collectively the returns have been poor, and the risk profile has gone up because of the sluggish performance by the FDA,” Rudnick told MedCity News. “What has happened is ... |
| Aug 24, 2012 | Novira Therapeutics raises $23M for hepatitis B treatment that attacks DNA of virus | Osvaldo (Lalo) Flores, the president and chief scientific officer of Novira Therapeutics in Radnor, Pennsylvania, told MedCity News in a phone interview that the biotechnology company’s capsid-targeting antivirals entering preclinical devel... |
| Jul 27, 2011 | Novira Therapeutics Completes Second Round of Seed Financing | Novira Therapeutics, Inc., a Radnor, Pennsylvania-based drug discovery company developing therapeutics for the treatment of viral diseases, including HBV and HIV, has completed a second round of seed financing. The round was led by three Ph... |
| Novira Therapeutics raises $23M for hepatitis B treatment that attacks DNA of virus | A biotechnology company with a novel drug treatment for hepatitis B and HIV patients could change the way drugs combat viruses. The drug, under development, which targets the outer shell, or capsids, of the viruses, has secured $23 million ... | |
| Attention life science startups: Super angel consortium seeks to fill investment void | A new investor group wants to bridge the funding gap to help life science companies navigate the valley of death between early stage and late-stage investment to meet significant milestones. Mid Atlantic Bio Angels was co-founded by Philade... |
Reviews 0
FAQ about Delaware Crossing Investor Group
What has the press written about Delaware Crossing Investor Group?
Parsers VC has collected 8 articles mentioning Delaware Crossing Investor Group, among them “Why I’m optimistic about Philly tech, and why you should be, too: Notes from a former investor” (Oct 8, 2020) and “New Castle’s ThruPore raises $540,000 from local investors” (Feb 21, 2018).
Is Delaware Crossing Investor Group still active?
Yes, Delaware Crossing Investor Group is active; its latest activity on Parsers VC dates from Oct 5, 2021.